Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

OBJECTIVE: The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients. METHODS: In a phase III study, patients naïve to biologic treatment were randomized to placebo, adalimumab 40 mg every 2 weeks (ADA; active reference) or ixekiz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatology (Oxford)
Main Authors: Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7516094/
https://ncbi.nlm.nih.gov/pubmed/32031665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kez684
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados